Human plasmacytoid dendritic cells and cutaneous melanoma

The prognosis of metastatic melanoma (MM) patients has remained poor for a long time. However, the recent introduction of effective target therapies (BRAF and MEK inhibitors for BRAFV600-mutated MM) and immunotherapies (anti-CTLA-4 and anti-PD-1) has significantly improved the survival of MM patients. Notably, all these responses are highly dependent on the fitness of the host immune system, including the innate compartment. Among immune cells involved in cancer immunity, properly activated plasmacytoid dendritic cells (pDCs) exert an important role, bridging the innate and adaptive immune responses and directly eliminating cancer cells. A distinctive feature of pDCs is the production of high amount of type I Interferon (I-IFN), through the Toll-like receptor (TLR) 7 and 9 signaling pathway activation. However, published data indicate that melanoma-associated escape mechanisms are in place to hijack pDC functions. We have recently reported that pDC recruitment is recurrent in the early phases of melanoma, but the entire pDC compartment collapses over melanoma progression. Here, we summarize recent advances on pDC biology and function within the context of melanoma immunity

Infection importation: a key challenge to malaria elimination on Bioko Island, Equatorial Guinea.

BACKGROUND: The impact of importation of falciparum malaria from mainland Equatorial Guinea on malaria infection in non-travellers and travellers on Bioko Island was examined. METHODS: Malaria indicator surveys were conducted in 2013 and 2014 to assess the association between malaria infection and travel to the mainland. Infection in non-travellers was compared in neighbourhoods of high travel and neighbourhoods of low travel. Boat passengers leaving from and arriving on the island were tested for infection. RESULTS: Children who had travelled to the mainland in the previous eight weeks were at greater risk of infection than those who had not travelled (56 vs 26% in 2013; 42 vs 18% in 2014). Children who had not travelled, living in localities with the highest proportion of travellers, were significantly more likely to be infected compared to those in localities with the smallest proportion of travellers (adjusted odds ratios 7.7 (95% CI 2.3-25) and 5.3 (95% CI 2.5-11) in 2013 and 2014, respectively). Infection in arriving boat passengers was substantially higher than in those departing (70 vs 38%, p = 0.017). DISCUSSION: Malaria importation by travellers poses a serious public health challenge affecting non-travellers as well as travellers

Tumor Infiltrating Neutrophils Are Enriched in Basal-Type Urothelial Bladder Cancer

15noBackground: Urothelial bladder cancers (UBCs) are distinct in two main molecular subtypes, namely basal and luminal type. Subtypes are also diverse in term of immune contexture, providing a rationale for patient selection to immunotherapy. Methods: By digital microscopy analysis of a muscle-invasive BC (MIBC) cohort, we explored the density and clinical significance of CD66b(+) tumor-associated-neutrophils (TAN) and CD3(+) T cells. Bioinformatics analysis of UBC datasets and gene expression analysis of UBC cell lines were additionally performed. Results: Basal type BC contained a significantly higher density of CD66b(+) TAN compared to the luminal type. This finding was validated on TCGA, GSE32894 and GSE124305 datasets by computing a neutrophil signature. Of note, basal-type MIBC display a significantly higher level of chemokines (CKs) attracting neutrophils. Moreover, pro-inflammatory stimuli significantly up-regulate CXCL1, CXCL2 and CXCL8 in 5637 and RT4 UBC cell lines and induce neutrophil chemotaxis. In term of survival, a high density of T cells and TAN was significantly associated to a better outcome, with TAN density showing a more limited statistical power and following a non-linear predicting model. Conclusions: TAN are recruited in basal type MIBC by pro-inflammatory CKs. This finding establishes a groundwork for a better understanding of the UBC immunity and its relevance.openopenMandelli, Giulio Eugenio; Missale, Francesco; Bresciani, Debora; Gatta, Luisa Benerini; Scapini, Patrizia; Caveggion, Elena; Roca, Elisa; Bugatti, Mattia; Monti, Matilde; Cristinelli, Luca; Belotti, Sandra; Simeone, Claudio; Calza, Stefano; Melocchi, Laura; Vermi, WilliamMandelli, Giulio Eugenio; Missale, Francesco; Bresciani, Debora; Gatta, Luisa Benerini; Scapini, Patrizia; Caveggion, Elena; Roca, Elisa; Bugatti, Mattia; Monti, Matilde; Cristinelli, Luca; Belotti, Sandra; Simeone, Claudio; Calza, Stefano; Melocchi, Laura; Vermi, Willia

Entrevistas a los ex integrantes de los Consejos de Redacción de Lecciones y Ensayos (1956-2016)

Fil: Ortiz, Tulio. Universidad de Buenos Aires. Facultad de Derecho. Cátedra Teoría del Estado-Profesor Emérito. Buenos Aires, ArgentinaFil: Díaz de Vivar, Elisa Matilde. Universidad de Buenos Aires. Facultad de Derecho. Cátedra Derecho Civil I. Buenos Aires, ArgentinaFil: Dulitzky, Ariel. Universidad de Buenos Aires. Facultad de Derecho.Cátedra Derechos Humanos. Buenos Aires, ArgentinaFil: Dulitzky, Ariel. Universidad de Buenos Aires. Facultad de Derecho. Cátedra Derecho Constitucional. Buenos Aires, ArgentinaFil: Ferrante, Marcelo. Universidad de Buenos Aires. Facultad de Derecho. Buenos Aires, ArgentinaFil: Bloch, Ivana Verónica. Universidad de Buenos Aires. Facultad de Derecho. Cátedra Elementos de Derecho Penal y Procesal Penal. Buenos Aires, ArgentinaFil: Bergallo, Paola. CONICET-Universidad de Buenos Aires. Facultad de Derecho. Buenos Aires, ArgentinaFil: Filippini, Leonardo G. Universidad de Buenos Aires. Facultad de Derecho. Centro de Estudios de Ejecución Penal (CEEP). Buenos Aires, ArgentinaFil: Sigal, Martín. Universidad de Buenos Aires. Facultad de Derecho. Centro de Derechos Humanos (CDH). Buenos Aires, ArgentinaFil: Bloch, Demise. Universidad de Buenos Aires. Facultad de Derecho. Buenos Aires, ArgentinaFil: Freedman, Diego. Universidad de Buenos Aires. Facultad de Derecho. Cátedra Finanzas Públicas y Derecho Tributario. Buenos Aires, ArgentinaFil: Pezzot, Romina. Universidad de Buenos Aires. Facultad de Derecho. Cátedra Derecho Internacional Público. Buenos Aires, ArgentinaFil: Hopp, Cecilia. Universidad de Buenos Aires. Facultad de Derecho. Cátedra Derecho Administrativo. Buenos Aires, ArgentinaFil: Rojas, Mishkila. Universidad de Buenos Aires. Facultad de Derecho. Proyectos DeCyT. Buenos Aires, ArgentinaFil: Garaventa, Carlos A. Universidad de Buenos Aires. Facultad de Derecho. Cátedra Derecho Público II. Buenos Aires, ArgentinaFil: Kenny, Patricio Enrique. Universidad de Buenos Aires. Facultad de Derecho. Cátedra Teoría General del Derecho. Buenos Aires, ArgentinaFil: Ramallo, María de los Ángeles. Universidad de Buenos Aires. Facultad de Derecho. Centro de Derechos Humanos (CDH). Buenos Aires, ArgentinaFil: Furfaro, Lautaro. Universidad de Buenos Aires. Facultad de Derecho; ArgentinaFil: Piqué, María Luisa. Universidad de Buenos Aires. Facutad de Derecho. Cátedra Elementos de Derecho Constitucional. Buenos Aires, ArgentinaFil: Benente, Mauro. Universidad de Buenos Aires. Facultad de Derecho. Instituto de Investigaciones Jurídicas y Sociales Ambrosio L. Gioja. Buenos Aires, ArgentinaFil: Etchegorry, María Alejandra. Universidad de Buenos Aires. Facultad de Derecho. Cátedra Derecho Internacional Privado. Buenos Aires, ArgentinaFil: Monti, Ezequiel. Universidad de Buenos Aires. Facultad de Derecho. Teoría General y Filosofía del Derecho. Buenos Aires, ArgentinaFil: Green Martínez, Sebastián. Universidad de Buenos Aires. Facultad de Derecho. Cátedra Derecho Internacional Público. Buenos Aires, ArgentinaFil: Bulit Goñi, Magdalena. Universidad de Buenos Aires. Facultad de Derecho. Buenos Aires, ArgentinaFil: Brodsky, Jonathan Matías. Universidad de Buenos Aires. Facultad de Derecho. Cátedra Obligaciones Civiles y Comerciales. Buenos Aires, ArgentinaFil: Olivera, Federico Eduardo. Universidad de Buenos Aires. Facultad de Derecho. Proyecto UBACyT. Buenos Aires, Argentin

Impaired activation of plasmacytoid dendritic cells via toll-like receptor 7/9 and STING is mediated by melanoma-derived immunosuppressive cytokines and metabolic drift

IntroductionPlasmacytoid dendritic cells (pDCs) infiltrate a large set of human cancers. Interferon alpha (IFN-α) produced by pDCs induces growth arrest and apoptosis in tumor cells and modulates innate and adaptive immune cells involved in anti-cancer immunity. Moreover, effector molecules exert tumor cell killing. However, the activation state and clinical relevance of pDCs infiltration in cancer is still largely controversial. In Primary Cutaneous Melanoma (PCM), pDCs density decreases over disease progression and collapses in metastatic melanoma (MM). Moreover, the residual circulating pDC compartment is defective in IFN-α production.MethodsThe activation of tumor-associated pDCs was evaluated by in silico and microscopic analysis. The expression of human myxovirus resistant protein 1 (MxA), as surrogate of IFN-α production, and proximity ligation assay (PLA) to test dsDNA-cGAS activation were performed on human melanoma biopsies. Moreover, IFN-α and CXCL10 production by in vitro stimulated (i.e. with R848, CpG-A, ADU-S100) pDCs exposed to melanoma cell lines supernatants (SN-mel) was tested by intracellular flow cytometry and ELISA. We also performed a bulk RNA-sequencing on SN-mel-exposed pDCs, resting or stimulated with R848. Glycolytic rate assay was performed on SN-mel-exposed pDCs using the Seahorse XFe24 Extracellular Flux Analyzer.ResultsBased on a set of microscopic, functional and in silico analyses, we demonstrated that the melanoma milieu directly impairs IFN-α and CXCL10 production by pDCs via TLR-7/9 and cGAS-STING signaling pathways. Melanoma-derived immunosuppressive cytokines and a metabolic drift represent relevant mechanisms enforcing pDC-mediated melanoma escape.DiscussionThese findings propose a new window of intervention for novel immunotherapy approaches to amplify the antitumor innate immune response in cutaneous melanoma (CM)

Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes

Ovarian carcinomas (OCs) are poorly immunogenic and immune checkpoint inhibitors (ICIs) have offered a modest benefit. In this study, high CD3+ T-cells and CD163+ tumor-associated macrophages (TAMs) densities identify a subgroup of immune infiltrated high-grade serous carcinomas (HGSCs) with better outcomes and superior response to platinum-based therapies. On the contrary, in most clear cell carcinomas (CCCs) showing poor prognosis and refractory to platinum, a high TAM density is associated with low T cell frequency. Immune infiltrated HGSC are characterized by the 30-genes signature (OC-IS30) covering immune activation and IFNγ polarization and predicting good prognosis (n = 312, TCGA). Immune infiltrated HGSC contain CXCL10 producing M1-type TAM (IRF1+pSTAT1Y701+) in close proximity to T-cells. A fraction of these M1-type TAM also co-expresses TREM2. M1-polarized TAM were barely detectable in T-cell poor CCC, but identifiable across various immunogenic human cancers. Single cell RNA sequencing data confirm the existence of a tumor-infiltrating CXCL10+IRF1+STAT1+ M1-type TAM overexpressing antigen processing and presentation gene programs. Overall, this study highlights the clinical relevance of the CXCL10+IRF1+STAT1+ macrophage subset as biomarker for intratumoral T-cell activation and therefore offers a new tool to select patients more likely to respond to T-cell or macrophage-targeted immunotherapies

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Objective: This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS). Methods: We retrospectively collected data of PwMS with suspected or confirmed COVID-19. All the patients had complete follow-up to death or recovery. Severe COVID-19 was defined by a 3-level variable: mild disease not requiring hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evaluated baseline characteristics and MS therapies associated with severe COVID-19 by multivariate and propensity score (PS)-weighted ordinal logistic models. Sensitivity analyses were run to confirm the results. Results: Of 844 PwMS with suspected (n = 565) or confirmed (n = 279) COVID-19, 13 (1.54%) died; 11 of them were in a progressive MS phase, and 8 were without any therapy. Thirty-eight (4.5%) were admitted to an ICU; 99 (11.7%) had radiologically documented pneumonia; 96 (11.4%) were hospitalized. After adjusting for region, age, sex, progressive MS course, Expanded Disability Status Scale, disease duration, body mass index, comorbidities, and recent methylprednisolone use, therapy with an anti-CD20 agent (ocrelizumab or rituximab) was significantly associated (odds ratio [OR] = 2.37, 95% confidence interval [CI] = 1.18-4.74, p = 0.015) with increased risk of severe COVID-19. Recent use (<1 month) of methylprednisolone was also associated with a worse outcome (OR = 5.24, 95% CI = 2.20-12.53, p = 0.001). Results were confirmed by the PS-weighted analysis and by all the sensitivity analyses. Interpretation: This study showed an acceptable level of safety of therapies with a broad array of mechanisms of action. However, some specific elements of risk emerged. These will need to be considered while the COVID-19 pandemic persists

DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France

We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39–3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18–0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon